For Healthcare & Life Sciences Professionals

Primary Analyst Photo	Document Information	Rate this Document
	April 26, 2005 Time To Revitalize Lagging Pharma Portals Use Audience and Process Insights To Rethink Portal Investment by Laura Ramos with Bradford J. Holmes, Sara E. McAulay, Shivika Asthana

This is an excerpt

Executive Summary

Life sciences firms bought portals early, but their initial projects ran aground as departmental pilots failed to cross organizational boundaries or finance prerequisite infrastructure like user directories, security, and common taxonomy. Doubling down on next-generation investments, pharma firms must revise their portal strategy investments now and apply them to role-based processes that bridge functional boundaries. Using portals to support collaborative, ad hoc processes, large drug manufacturers will build Innovation Networks that offer big payoffs in new drug innovation and adaptive clinical trials.

TABLE OF CONTENTS

• Pharma Firms Let Portals Drift Off Course
• Revisit Portal Business Case By Focusing On Audience And Process
• Portals Drive Drug Discovery And Clinical Trial Payoffs Via Innovation Networks

RECOMMENDATIONS

• How Pharma Can Keep Portal Projects On The Right Track

WHAT IT MEANS

• Interaction Platforms Support Innovation Networks
• Supplemental Material
• Related Research Documents

This is an excerpt

Buy Risk-Free

Price: US $499

Our Service Guarantee: If you are not completely satisfied with this document, notify Forrester within 24 hours of purchase for a full refund.

Already a Forrester Client?
Log in to read this document.